No of events / total								No of events / total		
Study	Experimental	Control		Odds Ratio [95% C] Study	Experimental	Control		Odds Ratio [95% CI]	
Tocilizumab			Favors Experimental	Favors Control	Baricitinib			Favors Experimental	Favors Control	
BACC-Bay	0/3	0/1	←	→ 0.43 [0.01, 33.6	00// DADDIED	9 / 106	15 / 118	-	0.64 [0.27, 1.52]	
COVIDOSE2-SS-A	0/6	1/2	-	0.08 [0.00, 2.9		57 / 612	82 / 592	—	0.64 [0.45, 0.91]	
ARCHITECTS	0/9	2/11	4	→ 0.20 [0.01, 4.7		16 / 43	26 / 44	•	0.41 [0.17, 0.97]	
CORIMUNO-TOCI-1	1 / 10	3 / 12	◆ •	0.33 [0.03, 3.8	RECOVERY Bari (No Toci)	306 / 2623	310 / 2525	H	0.94 [0.80, 1.12]	
CORIMUNO-TOCI-ICU	4/8	2/4	←	1.00 [0.09, 11.0	T-+- [050/ C-1]		433 / 3279	_	0.70 [0.50, 4.00]	
ImmCOVA	2/21	2/26	-	→ 1.26 [0.16, 9.8	Total [95% Crl] τ = 0.16 [95% Crl: 0.03,	388 / 3384			0.78 [0.56, 1.03] PI: [0.44, 1.26]	
COV-AID	6 / 48	3 / 42	<u> </u>	→ 1.86 [0.43, 7.9	t = 0.16 [95 % C11. 0.03,	0.30]			F1. [0.44, 1.20]	
HMO-020-0224	10 / 31	8 / 15	•	O.42 [0.12, 1.4] Sarilumab					
TOCIBRAS	8 / 31	5 / 34	<u> </u>	→ 2.02 [0.58, 7.0	CORIMUNO-SARI-1	0.40	0 / 4		0.14[0.00_4.47]	
COVACTA	14 / 56	12 / 41	ı	0.81 [0.33, 1.9	REGENERON-P2	0/3	2/4		→ 0.14 [0.00, 4.47] → 1.39 [0.42, 4.62]	
EMPACTA	24 / 200	11 / 112	<u> </u>	1.25 [0.59, 2.6		27 / 62 84 / 345	5 / 14 24 / 99		1.01 [0.60, 1.69]	
PreToVid	20 / 159	32 / 167	⊢ • :	0.61 [0.33, 1.1		8 / 44	13 / 52		0.67 [0.25, 1.79]	
REMDACTA	69 / 358	39 / 181	<u> </u>	─		1 / 17	0/8		1.55 [0.06, 42.15]	
REMAP-CAP	53 / 214	73 / 217	⊢ •—	0.65 [0.43, 0.9		2/66	3 / 34	4.	0.32 [0.05, 2.03]	
RECOVERY Toci	482 / 1664	600 / 1721	н⊕н	0.76 [0.66, 0.8		2/70	1/70	•	◆ 2.03 [0.18, 22.91]	
Total [95% Crl]	693 / 2818	793 / 2586	•	0.78 [0.65, 0.9		124 / 607	48 / 281		0.92 [0.60, 1.41]	
τ = 0.11 [95% Crl: 0.02, 0	251			PI: [0.56, 1.1	$\tau = 0.13 [95\% Crl: 0.02,$				PI: [0.52, 1.62]	
v = 0.11 [0070 011. 0.02, 0	5.20]			1 1. [0.00, 1.1	,					
			0.25 0.5 1	2 4				0.25 0.5	1 2 4	
			Odds Ratio	(log scale)			Odds Ratio (log scale)			